Skip to main content

The Company held an analyst conference call on 12 May 2022 at 13.30 CET/07.30 EST. 

To launch the audio webcast recording of the call please click on this link

Slides for the call can be downloaded below.

The first quarter of 2022 was a key moment in the Company’s history following the report of positive data for leniolisib in a pivotal study in patients with activated phosphoinositide 3-kinase delta syndrome.

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline